Gene therapy for B cell lymphomas

A. K. Fielding, Stephen J Russell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The use of genes or genetically modified cells for therapeutic benefit is likely to have a significant therapeutic role for patients with B cell lymphomas in the future. To date, most gene therapy strategies applicable to the therapy of these diseases have not reached the point of clinical study. Adoptive immunotherapy using donor leucocyte infusions to treat aggressive B cell neoplasms in immunosuppressed patients has, however, shown great promise clinically, and studies of idiotypic vaccination in patients with low grade B cell neoplasms are also under way. Results from in vitro and animal studies continue to suggest that it may become possible to use the immune system for therapeutic benefit, and many current basic research strategies in the gene therapy of B cell non-Hodgkin's lymphoma are based on immune modulation of T cells or tumour cells themselves. Other major approaches to gene therapy for B cell malignancies include the introduction of directly toxic or 'suicide genes' into B cells or the chemoprotection of haemopoietic stem cells by the introduction of drug resistance genes. All of these approaches require efficient and accurate gene transfer as well as correct expression of the gene product within the target cell. Although some way from therapeutic use, specific targeting of gene delivery is an area of active investigation and will be of value in many of the gene therapy strategies applicable to B cell lymphomas.

Original languageEnglish (US)
Pages (from-to)327-342
Number of pages16
JournalCancer Surveys
Volume30
StatePublished - 1997
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Genetic Therapy
B-Lymphocytes
Genes
Neoplasms
Adoptive Immunotherapy
Gene Targeting
Poisons
Therapeutic Uses
Therapeutics
Drug Resistance
Non-Hodgkin's Lymphoma
Suicide
Immune System
Vaccination
Leukocytes
Stem Cells
Tissue Donors
T-Lymphocytes
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gene therapy for B cell lymphomas. / Fielding, A. K.; Russell, Stephen J.

In: Cancer Surveys, Vol. 30, 1997, p. 327-342.

Research output: Contribution to journalArticle

Fielding, AK & Russell, SJ 1997, 'Gene therapy for B cell lymphomas', Cancer Surveys, vol. 30, pp. 327-342.
Fielding, A. K. ; Russell, Stephen J. / Gene therapy for B cell lymphomas. In: Cancer Surveys. 1997 ; Vol. 30. pp. 327-342.
@article{a974c923a9c94805871fc61a4271d43d,
title = "Gene therapy for B cell lymphomas",
abstract = "The use of genes or genetically modified cells for therapeutic benefit is likely to have a significant therapeutic role for patients with B cell lymphomas in the future. To date, most gene therapy strategies applicable to the therapy of these diseases have not reached the point of clinical study. Adoptive immunotherapy using donor leucocyte infusions to treat aggressive B cell neoplasms in immunosuppressed patients has, however, shown great promise clinically, and studies of idiotypic vaccination in patients with low grade B cell neoplasms are also under way. Results from in vitro and animal studies continue to suggest that it may become possible to use the immune system for therapeutic benefit, and many current basic research strategies in the gene therapy of B cell non-Hodgkin's lymphoma are based on immune modulation of T cells or tumour cells themselves. Other major approaches to gene therapy for B cell malignancies include the introduction of directly toxic or 'suicide genes' into B cells or the chemoprotection of haemopoietic stem cells by the introduction of drug resistance genes. All of these approaches require efficient and accurate gene transfer as well as correct expression of the gene product within the target cell. Although some way from therapeutic use, specific targeting of gene delivery is an area of active investigation and will be of value in many of the gene therapy strategies applicable to B cell lymphomas.",
author = "Fielding, {A. K.} and Russell, {Stephen J}",
year = "1997",
language = "English (US)",
volume = "30",
pages = "327--342",
journal = "Cancer Surveys",
issn = "0261-2429",
publisher = "Cold Spring Harbor Laboratory Press",

}

TY - JOUR

T1 - Gene therapy for B cell lymphomas

AU - Fielding, A. K.

AU - Russell, Stephen J

PY - 1997

Y1 - 1997

N2 - The use of genes or genetically modified cells for therapeutic benefit is likely to have a significant therapeutic role for patients with B cell lymphomas in the future. To date, most gene therapy strategies applicable to the therapy of these diseases have not reached the point of clinical study. Adoptive immunotherapy using donor leucocyte infusions to treat aggressive B cell neoplasms in immunosuppressed patients has, however, shown great promise clinically, and studies of idiotypic vaccination in patients with low grade B cell neoplasms are also under way. Results from in vitro and animal studies continue to suggest that it may become possible to use the immune system for therapeutic benefit, and many current basic research strategies in the gene therapy of B cell non-Hodgkin's lymphoma are based on immune modulation of T cells or tumour cells themselves. Other major approaches to gene therapy for B cell malignancies include the introduction of directly toxic or 'suicide genes' into B cells or the chemoprotection of haemopoietic stem cells by the introduction of drug resistance genes. All of these approaches require efficient and accurate gene transfer as well as correct expression of the gene product within the target cell. Although some way from therapeutic use, specific targeting of gene delivery is an area of active investigation and will be of value in many of the gene therapy strategies applicable to B cell lymphomas.

AB - The use of genes or genetically modified cells for therapeutic benefit is likely to have a significant therapeutic role for patients with B cell lymphomas in the future. To date, most gene therapy strategies applicable to the therapy of these diseases have not reached the point of clinical study. Adoptive immunotherapy using donor leucocyte infusions to treat aggressive B cell neoplasms in immunosuppressed patients has, however, shown great promise clinically, and studies of idiotypic vaccination in patients with low grade B cell neoplasms are also under way. Results from in vitro and animal studies continue to suggest that it may become possible to use the immune system for therapeutic benefit, and many current basic research strategies in the gene therapy of B cell non-Hodgkin's lymphoma are based on immune modulation of T cells or tumour cells themselves. Other major approaches to gene therapy for B cell malignancies include the introduction of directly toxic or 'suicide genes' into B cells or the chemoprotection of haemopoietic stem cells by the introduction of drug resistance genes. All of these approaches require efficient and accurate gene transfer as well as correct expression of the gene product within the target cell. Although some way from therapeutic use, specific targeting of gene delivery is an area of active investigation and will be of value in many of the gene therapy strategies applicable to B cell lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=0030865182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030865182&partnerID=8YFLogxK

M3 - Article

C2 - 9548000

AN - SCOPUS:0030865182

VL - 30

SP - 327

EP - 342

JO - Cancer Surveys

JF - Cancer Surveys

SN - 0261-2429

ER -